The HESI eSTAR Committee is chairing a session titled "Omics to facilitate more accurate translation from non-clinical models to human health".
2025 Toxicology Forum Winter Meeting
February 11, 2025 – February 13, 2025
Raleigh, North Carolina, US
The mission of HESI’s Emerging Systems Toxicology for the Assessment of Risk (eSTAR) Committee is to develop and deliver innovative systems toxicology approaches for risk assessment. The committee aims to catalyze adoption of new translational and predictive tools that guide decision-making based on mechanistic understanding of toxicological response.
This project is developing transcriptomic-based biomarkers that will be predictive of particular molecular initiating events leading to rat liver tumors. The group has also launched an experimental study in wildtype & knockout rats for molecular initiating events.
This Consortium has initiated the design and implementation of a pioneering experimental study to advance integration of in vitro ‘omics approaches (Cell Painting, transcriptomics, and proteomics) into safety evaluation. The Massachusetts Life Sciences Center (MLSC) grant has been awarded to our nonprofit partner, the Broad Institute, at $1,000,000! Matched with contributions from our 16 industry partners, we expect a total project budget of approximately $4.2 million.
This group is exploring the use of error corrected sequencing to identify non-genotoxic tumorigenic agents in rodents. An inventory of samples from members was compiled that can be used to measure cancer driver genes. A pilot study has been completed comparing study designs to detect clonal expansion.
This team designed a study looking at the effect of different nephrotoxicants on multiple miRNAs using an in vitro model for proximal tubule cells. They also conducted a multi-site experimental program on the use of exosomal miRNAs expressed in response to renal toxicants; manuscript published in 2024.
This group was awarded a $250,000 USD grant (U01) as part of the US FDA’s Biomarker Qualification Program in 2022. This funding was partnered with Committee resources to support a four-site ring trial generating additional data on the TGx-DDI biomarker. Submission package is being prepared for qualification and the group is exploring other opportunities such as the OECD Test Guideline process.
Learn more about the use of the TGx-DDI transcriptomic biomarker for the genotoxicity assessment of data-poor chemicals here (poster presented at the 2021 EMGS Virtual Annual Meeting by Anne-Marie Fortin, University of Ottawa).
This Working Group has compiled a broad membership of experts across sectors and chemical classes to write a recently accepted manuscript on the state of the science on the use and potential applications of transcriptomic PODs. Future work will include discussion of bioinformatic methods to derive transcriptomic PODs.
FFPE Project: A manuscript on DNA de-modification analysis of clinical tumor samples was accepted; the project will sunset after an educational webinar.
No results.
Director, Center for Patient and Consumer Safety (CPCS)
spettit@hesiglobal.orgGlaxoSmithKline
National Institute of Environmental Health Sciences
Syngenta
February 11, 2025 – February 13, 2025
Raleigh, North Carolina, US
The HESI eSTAR Committee is chairing a session titled "Omics to facilitate more accurate translation from non-clinical models to human health".
February 13, 2025 – February 14, 2025
Virtual, Online
March 16, 2025 – March 20, 2025
Orlando, Florida, USA
HESI will attend the 2025 Society of Toxicology Annual Meeting and Tox Expo in Orlando, Florida. Click for details.
June 24, 2025 – June 26, 2025
Durham, NC, USA
The HESI eSTAR Committee is holding a workshop to discuss research questions related to transcriptomic point of departures (tPODS), focusing on the bioinformatic differences. We will identify research gaps, present case studies, and dive into datasets.
September 14, 2025 – September 17, 2025
Athens, Greece
HESI is proud to have two committees contributing to the EuroTox 2025 program, which will take place in Athens, Greece, from 14–17 September 2025. These sessions highlight HESI's commitment to advancing innovative approaches in toxicology.
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-8403
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.